carboplatin + demcizumab + pemetrexed

The combination of carboplatin, demcizumab, and pemetrexed is an investigational treatment regimen that has been studied primarily for non-squamous non-small cell lung cancer (NSCLC). This combination brings together a platinum-based chemotherapy agent (carboplatin), an anti-cancer stem cell agent targeting DLL4 (demcizumab), and an antifolate antineoplastic agent (pemetrexed). ## Mechanism and Development Demcizumab is a humanized IgG2 anti-DLL4 antibody that inhibits tumor growth by targeting the Notch ligand Delta-like ligand 4 (DLL4). It works by decreasing cancer stem cell frequency and producing an antiangiogenic effect[2]. When combined with standard chemotherapy agents carboplatin and pemetrexed, this regimen showed promising results in early clinical trials. The combination was evaluated in a Phase 1b study where patients received demcizumab at various doses (2.5, 5.0, or 7.5 mg/kg) along with standard doses of pemetrexed (500 mg/m²) and carboplatin (AUC = 6)[1][2]. Initially, continuous demcizumab was given until progression, but after two patients developed grade 3 pulmonary hypertension and congestive heart failure after eight or more infusions, a truncated regimen was implemented[1]. In the Phase 1b trial, the overall response rate was 50%, with a disease control rate of 88%[2][6]. Among patients who received the truncated demcizumab dosing schedule, the clinical benefit rate was 93%[6]. ## Clinical Development Status OncoMed Pharmaceuticals initiated a Phase 2 clinical trial called DENALI to test this combination in 2015[6][8]. The trial was designed to enroll approximately 200 patients with first-line metastatic Stage IV non-squamous NSCLC whose tumors did not have EGFR or ALK mutations[8]. The recommended Phase 2 dose of demcizumab was determined to be 5 mg/kg given every 3 weeks for 4 cycles (truncated regimen) in combination with standard carboplatin and pemetrexed chemotherapy[1]. This combination represents an approach that combines traditional chemotherapy with targeted therapy against cancer stem cells, potentially offering improved outcomes for patients with non-squamous NSCLC.

Brand names

Alimta